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INTRODUCTION
The common view on how cardiomyocytes die
during or after myocardial infarction has altered in
recent years. For a long time necrosis was regarded
as the sole cause of cell death inmyocardial infarction.
Now, recent studies indicate that apoptosis also plays
a role in the process of tissue damage subsequent
to myocardial infarction (1-4). Cardiotrophin-1 (CT-1)
is a new member of the interleukin (IL)-6 family of
cytokines. A 1.7 kb CT-1 mRNA is expressed in the
human heart and several other tissues. CT-1 shares
the signal transducing receptor components gp 130
and leukemia inhibitory factor receptor (LIFR) with
the previously identifiedmembers of the IL-6 cytokine
family. CT-1 is expressed at high levels in the myocar-
dium during the course of cardiogenesis, and promotes
the proliferation and survival of embryonic cardio-
myocytes. CT-1 may therefore play an important role
in several cardiovascular diseaseswith cardiachypertro-
phy aswell as heart failure (5-7).More recently, several
investigations have demonstrated that CT-1 could
effectively reduce myocardial ischemia/reperfusion
injury (8 -11) and prevent cardiomyocyte apoptosis (12)
in vitro . However, whether CT-1 plays an important
role in postischemic myocardial apoptosis in vivo has
not been determined. Therefore, the present study
was undertaken to determine the effects of CT-1 on
hemodynamics, cardiac function, cardiomyocyte apop-
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tosis, as well as expression of P53, Fas, Bax and Bcl-2
proteins in a rat model of acute myocardial infarction.
MATERIAL AND METHODS
1)Rat infarct model
Twenty-four male Sprague-Dawley rats weighing
approximately 310 gwere used for this study.The rats
were subjected to left anterior descending coronary
artery ligation which produced extensive acute myo-
cardial infarction (about 35% of left ventricle) as our
previous reports (13, 14), with 12 rats for eachgroup. The
animals were anesthetized by intraperitoneal injec-
tion of ketamine hydrochloride (80mg/kg), intubated
via tracheotomy, and mechanically ventilated with
a volume-cycled small-animal respirator. Anterolateral
thoracotomy was performed, and the heart was rapidly
exteriorized. One or two 5-0 silk sutures were snared
in a blinded manner around the proximal left anterior
descending coronary artery and then tightly ligated
to occlude the vessel. The heart was then replaced,
the lungs were reexpanded, and the chest was closed
in three layers with 4-0 silk sutures. The animals were
kept under mechanical ventilation until they awoke
from anesthesia. The study protocol was approved
by the Administrative Panel on Laboratory Animal Care
of Guangxi Medical University, China.
2)Administration of CT-1
Seven days before surgery, the rats were randomized
to receive CT-1(treated group) or phosphate-buffered
saline (PBS, control group). 2µg recombinant rat CT-1
(Prepro Tech EC Ltd., London, UK) in 1 ml PBS was
injected daily via the tail vein for 7 days. Control rats
received an equal volume of PBS alone (n=12 for each
group).
3)Hemodynamic monitoring
Twenty-four hours after the surgery, the animals
were again anesthetized. A longitudinal incision was
then performed in the right cervical part. Through this
incision, the right internal carotid artery was isolated
and controlled using vessel loops. A polyethylene-
50 catheter filled with heparin and saline (200IU/ml)
was then inserted through the right internal carotid
artery into the left ventricular cavity and connected
to a pressure transducer. Left ventricular pressure was
continually recorded on a PowerMacintosh computer
via a data acquisition system. The left ventricular systolic
pressure (LVSP), left ventricular end-diastolic pressure
(LVEDP), the maximum rate of left ventricular pressure
rise or fall (±dP/dtmax), and heart rate (HR)were auto-
matically analyzed. Mean arterial pressure (MAP)
was calculated from the carotid arterial pressure recorded
in the right internal carotid artery. At the completion
of physiologic measurements, the chest was opened
and the heart excised. The atria were separated, the
blood in the ventricular chambers removed, the left
ventricle inclusive of the septum and right ventricle
dissected, and their weights collected. The left ven-
tricle was cut into four transverse slices from apex to
base. The slices were fixed at 24 hours in 10% formalin,
embedded in paraffin, and cut into 4 µm sections.
4)Terminal deoxynucleotidyl transferase-mediated
dUTP-Biotin in situ nick-end labelling (TUNEL)
Sections weremounted on poly-L-lysine-coated slides.
After deparaffinization and rehydration, tissue sections
were incubatedwith proteinase K (20 µg/ml in10mM
Tris-HCl, pH 7.6) for 30 minutes at 21 to 37℃. Sections
were rinsed twice with PBS and incubated with block-
ing solution(0.3% H2O2 inmethanol) for 1 hour at room
temperature. DNA strand breakswere detected using
the terminal deoxynucleotidyl transferase mediated
dUTP nick end labelling method (TUNEL). The re-
agents were all fromRocheDiagnostics (HongKong)
Limited. Briefly, sections were covered with 50 µl of
TUNEL reaction mixture, and incubated in this so-
lution for 60 minutes at 37℃ in a humidified cham-
ber. After rinsing in PBS, the sections can be analyzed
under a fluorescence microscope. Subsequently, the
samples were covered with 50 µl of converter-POD
(anti-fluorescein antibody, Fab fragment from sheep,
conjugated with horse-radish peroxidase), and incu-
bated in a humidified chamber for 30 minutes at 37℃.
Sections were rinsed three times with PBS. Finally,
sections were covered with AEC-substrate solution
(50 to 100 µl), and incubated for 10 minutes at room
temperature. Sections were rinsed three times with
PBS again. The sectionswere faintly counterstained with
hematoxylin before coverslipping with AEC-mounting
solusion. The number of apoptotic cardiomyocytes and
their percentage of total cardiomyocytes were counted
with the use of a microscope. Cardiomyocytes from at
least 3 sections per animal that were randomly selected
were evaluated immunohistochemically to determine
the number and percentage of cells exhibiting positive
staining for apoptosis. For each slide 5 fields were
randomly chosen, and by using a defined rectangular
field area (×40 objective), a total of 200 cells per field
were counted. The index of apoptosis was determined
(ie, number of apoptotic cardiomyocytes divided by
the total number of cardiomyocytes counted×100)
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from a total of 15 fields per heart, and the assays were
performed in a blinded manner.
5)Immunohistochemical staining of P53, Fas, Bax,
and Bcl-2 proteins in myocardium
Immunohistochemical staining for P53, Fas, Bax,
and Bcl-2 proteins was performed on three cross-
sections serially cut at 4-µm intervals fromeach animal.
Briefly, this involved blocking endogenous peroxidase
with 3% hydrogen peroxide, preincubation in blocking
serum, and application of the primary antibody (Santa
Cruz Biotechnology, Inc.) at the appropriate dilution
(ie, 1 : 80) overnight at 4℃. A biotinylated secondary
antibody was then applied for 30 minutes at room
temperature followed by streptavidin-horseradish-
peroxidase complex. After 30minutes at room tempera-
ture, sections rinsed with PBS and visualized by in-
cubation with 0.05% (w/v) 3, 3’-diaminobenzidine tetra-
hydrochloride dehydrate. Slides were counterstained
with hematoxylin before coverslipping. The value of
optical density is monitored with computer-assisted
image analysis (LEICA Q 550 IW). For each slide 5
fields were randomly chosen. The value ofmean optical
density was calculated. The assays were performed
in a blinded manner.
6)Statistical analysis
All values in the text and tables are presented as
mean±SD. Comparisons between two groups were
made using unpaired Student’s t test. A value of P<
0.05 was considered to have statistical significance.
RESULTS
1)Effect of CT-1 on hemodynamics
The MAP, LVSP and±dP/dtmax in CT-1 treatedgroup
were significantly higher than those in control group,
respectively. On the contrary, the LVEDP in treated
group was significantly lower than that in control group.
CT-1 pretreatment did not affect theHR, heart weight,
body weight or the ratio of heart weight to body
weight (Table 1).
2)Effect of CT-1 on cardiomyocyte apoptosis
TUNEL stainingmethod showed thatmany apoptotic
cardiomyocytes were observed in the border zone
of infarcted tissue in both control and treated animals.
The nuclei of the apoptotic cardiomyocytes were red
of fluorescence labelling. The amount of apoptotic
cardiomyocytes in CT-1 treated group was signifi-
cantly less than that in control group [(15.8±5.2)% vs
(34.6±7.7)%, P <0.01](Figure 1).
3)Effect of CT-1 on expression of myocardial P53, Fas,
Bax and Bcl-2
Immunohistochemical staining showed that P53
immunoreactivity was found in the tissue adjacent to
infarcted zone in both control and treated groups. The
intensity of P53 protein expressionwas coincident with
the number of cardiomyocyte apoptosis. P53 immunore-
active product was mainly located in the nuclei. The
mean optical density in treated group was lower than
that in control group (Table 2 and Figure 2) ; Fas
immunoreactivity was yellow-brown product. The im-
munoreactive product was located in the membrane
and cytoplasm of cardiomyocytes. The mean optical
density of Fas protein in treated groupwas lower than
that in control group (Figure 3) ; Bax immunoreactivity
was yellow-brown reactive product which located in
the cytoplasm of cardiomyocytes. The mean optical
density of Bax protein in treated groupwas also lower
than that in control group (Figure 4) ; Bcl-2 labelling
in cardiomyocytes was distributed in the cytoplasm.
Table 1. Comparisons of hemodynamic characteristics and heart weight between control and treated groups (mean ±SD).
Control group Treated group
HR(beats/min)
MAP(mmHg)
LVSP(mmHg)
LVEDP(mmHg)
+dP/dtmax(mmHg/s)
-dP/dtmax(mmHg/s)
HW(mg)
BW(g)
HW/BW(mg/g)
385.38±12.74
91.62±6.83
114.26±7.74
14.79±3.85
4489.76±353.79
3428.57±321.48
1041.55±49.21
308.26±15.47
3.38±0.24
378.32±13.45
103.77±7.63＊
125.88±6.43＊
9.33±2.68＊
5412.28±362.52＊＊
4131.18±286.44＊＊
1054.33±51.86
311.66±14.87
3.39±0.21
HR=heart rate ; MAP=mean arterial pressure ; LVSP=left ventricular systolic pressure ; LVEDP=left ventricular end-diastolic pressure ;
±dP/dtmax=the maximum rate of left ventricular pressure rise (＋dP/dtmax) or fall (－dP/dtmax) ; HW=heart weight ; BW=body weight ;
HW/BW= the ratio of heart weight to body weight ; ＊P <0.01,＊＊P <0.001 in comparison with control group.
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Figure 1. Myocardial sections of control (A) and treated (B) animals, the number of apoptotic myocytes (with intensely red
nuclei) determined with terminal deoxynucleotidyl transferase-mediated dUTP-fluorescein nick end labelling (TUNEL) method
is more in control section than that in treated section. TUNEL method×400
A B
Figure 2. Immunohistochemical (IHC) staining for P53 of myocardial sections of control (A) and treated (B) animals, P53
immunoreactivity is stronger in control section than that in treated section. P53 immunoreactive substance was mainly located in
the nuclei. IHC method×400
A B
Figure 3. Immunostaining for Fas of myocardial sections of control (A) and treated (B) rats, Fas immunoreactivity is stronger
in control section than that in treated section. Fas immunoreactive substance was located in the cytoplasm. IHC method×４００
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The mean optical density of Bcl-2 protein in treated
group was significantly higher than that in control
group (Figure 5).
DISCUSSION
The chronic effects of CT-1 on hemodynamics and
cardiac function are still unclear. Jin et al.(15) have
reported that intravenous administration of CT-1
caused a dose-dependent decrease in MAP, and an
increase in HR. CT-1 (100µg/kg) significantly elevated
cardiac output and HR, and decreased MAP and sys-
temic vascular resistance. Stroke volumewas unaltered.
There was no significant difference in left ventricular
maximal dP/dt between the CT-1-treated and vehicle-
Table２. Comparisons of mean optical density of myocardial P53, Fas, Bax and Bcl-2 proteins between control and treated
groups (mean±SD).
Control group Treated group
P53
Fas
Bax
Bcl-2
0.12±0.02
0.14±0.03
0.15±0.04
0.13±0.02
0.07±0.02＊
0.09±0.03＊
0.08±0.03＊＊
0.18±0.04＊
＊P <0.05,＊＊P <0.01 in comparison with control group.
A B
Figure 4. Immunohistochemically stained views for Bax of myocardial sections of control (A) and treated (B) rats, Bax
immunoreaction is stronger in control section than that in treated section. The yellow-brown reactive product was distributed in
the cytoplasm. IHC method×４００
A B
Figure 5. Immunostaining for Bcl-2 of myocardial section of control (A) and treated (B) rats, Bcl-2 immunoreactivity is
stronger in treated section than that in control section. The immunoreactive substance was mainly distributed in the cytoplasm.
IHC method×400
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treated groups. Yao et al. (16) showed that CT-1 injection
significantly decreased blood pressure and significantly
increased HR in spontaneously hypertensive rats and
Wistar Kyoto rats. Themost obvious change occurred
within 10 minutes after injection. However, there was
no significant difference in the hypotensive effect of
CT-1 on 10-week-old spontaneously hypertensive rats
and Wistar Kyoto rats. Hamanaka et al. (17) have also
demonstrated that intravenous injection of CT-1(4-
100µg/kg) in conscious rats evoked significant declines
in blood pressure and reflex increases inHR in a dose-
dependent manner. CT-1 induced no significant change
in cardiac output, whichwascompatiblewith the results
from isolated perfused rathearts ;HR, change inpressure
over time, left ventricular developed pressure, and
perfusion pressure were unaffected. However, in the
present study we showed that pretreatment with CT-1
for 7 days is capable of significantly increasing MAP,
LVSP and ±dP/dtmax, and significantly loweringLVEDP.
CT-1 pretreatment did not affect theHR, heart weight,
body weight or the ratio of heart weight tobodyweight
in the rat model of acute myocardial infarction. The
reason for this discrepancymaybe related to the dosage
and course of CT-1 administration. In our current study,
the dose of CT-1 is relative small, furthermore, the
hemodynamic parameters weremeasured at 24hours
after the last injection of CT-1, thus the results of the
present studymay be thought to be the chronic effects
of CT-1 on hemodynamics and cardiac function.
Myocardial infarctionhasbeenconsideredtobeaprime
example ofnecrotic cell death, becauseof thebreakdown
of cellular energy metabolism. However, apoptosis of
cardiomyocytes also occurs in a temporally and spatially
specific manner(1-4). Thus, acutemyocardial infarction
manifests both forms of cell death, with apoptosis par-
ticularly occurring at the hypoperfused“border”zones,
between a central area of necrosis and viable myo-
cardium. The central, unperfused region alsomanifests
apoptosis, particularly within the first sixhours, although
between 6 to 24 hours necrosis ismore common. Apop-
tosis in the remote non-infarctedmyocardiummay be
partly responsible formyocardialremodellinganddilatation
after myocardial infarction (1-4).Cardiomyocyte apoptosis
was found to contribute independently to the evolution
of infarct size(1). Studies in theventricular cardiomyocytes
of the hearts of patients who died of acute myocardial
infarction have shown that apoptosis plays a role in
the process of cell death of cardiomyocytes. Saraste
et al . (2) showed, inmyocardial samplesobtained from
patients who died of acute myocardial infarction, that
in addition to overt necrosis, a subset of cardiomyocytes
undergoes apoptosis during ischemia/reperfusion
injury. The apoptotic cardiomyocytesweremost promi-
nent in the border zones of recent infarction, whereas
very few apoptotic cells were present in the remote
non-infarcted myocardium. The time course of car-
diomyocyte apoptosis after myocardial infarction re-
mains unclear. In a previous study, Kajstura and col-
leagues(1)reported that dUTP-stained cardiomyocyte
nuclei were not observed in sham-operated control
animals and in infarcted rats20minutes and1hour.
Labelled cardiomyocytes were detected first at 2 hours
and did not vary at 3 hours, increased markedly at 4.5
hours, and decreased gradually at 6 hours and sharply
at 7 days after coronary artery occlusion. Zhu et al.(3),
however, reported that the strongest staining of apop-
tosis was detected in rats 3 days post operation.Weak
staining was found 1-day and 7-day post myocardial
infarction. Very few apoptotic cells were detected in
the rats 2 weeks after myocardial infarction. In the
present study, wehave shown that cardiomyocyte apop-
tosis increases significantly at 24 hours after rat myo-
cardial infarction. In all animals, clusters of apoptotic
cardiomyocytes were detected particularly in the
border zones of infarctedmyocardium.Manyapoptotic
cells were also present in the endocardial regions
adjacent to infarction. Therefore, it was suggested
that apoptosis is the major determinant of infarct size.
The reason of enhancing apoptosis in the border zones
of infarcted myocardium may be hypoxia and ischemia
of the myocardium. Experimental evidence suggests
that cardiomyocytes are able to undergo apoptosis
during hypoxia and ischemia. Factors known to asso-
ciated with both ischemia-reperfusion injury and apop-
tosis include oxygen-derived free radicals and altera-
tions of intracellular calcium homeostasis (18, 19). In
the present studywe also show that pretreatment with
CT-1 for 7 days is capable of significantly reducing car-
diomyocyte apoptosis, suggesting that CT-1 has a pro-
tective effect for the heart. The cardioprotection of CT-1
may be realized bymeans of improving hemodynamics,
stimulating cardiomyocyte hypertrophy, inhibiting
P53, Fas and Bax expression, and increasing Bcl-2
expression. In a previous study, Sheng et al. (12) have
demonstrated that CT-1 promotes cardiomyocyte sur-
vival via the activation of an antiapoptotic signaling path-
way that requires mitogen-activated protein kinases,
whereas the hypertrophy induced byCT-1may beme-
diated by alternative pathways, e.g. Janus kinase/signal
transducer and activator of transcriptionorMEKkinase/
c-Jun NH 2-terminal protein kinase (11, 20).
Apoptosis is a morphologically distinct, genetically
controlled type of cell death. Extensive fragmentation
of genomic DNA into nucleosome-sized fragments
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by endogenous endonucleases is the biochemical
hallmark of apoptosis. Apoptosis can be influenced by
a wide variety of regulatory stimuli. Apoptoticgenesmay
have an important function in regulating apoptosis.
One hypothesised general molecular mediator of hy-
poxia inducedapoptosis is the tumor suppressor transcrip-
tion factor P53. Exposure of cardiomyocytes tohypoxia
for 48 hours resulted in intranucleosomal cleavage of
genomic DNA characteristic of apoptosis and was
accompanied by increased P53 transactivating activity
and protein accumulation (21).Upregulation of P53
can induce cardiomyocyte apoptosis by stimulating
the expression of Bax and/or repression of Bcl-2 ex-
pression. In contrast, in an in vivo model of apopto-
sis in wild-type mice and homozygous P53 knockout
mice, it was found that ischemia induced apoptosis
occurred as readily in the P53 knockout mice as in
wild-type mice (22). This finding indicates the existence
in the heart of other, P53 independent, mechanisms
of postischemic apoptosis. Results in this investigation
show that the expression of P53 in cardiomyocytes
of the left ventricular free wall increased significantly
at 24 hours after coronary artery occlusion, and this
phenomenon indicates that P53 may involve in cardio-
myocyte apoptosis after myocardial infarction.
Fas antigen belongs to the family of cell surface
protein that includes tumor necrosis factor receptor,
nerve growth factor receptor, B-cell antigen CD40,
and T-cell antigenOX40 (23). Apoptosis can be induced
by Fas antigen-antibody interaction in various cell lines.
Tanaka et al.(24) showed thatmessenger RNA for Fas
antigen was expressed in both cardiomyocytes and
nonmyocytes as revealed by Northern blotting and
in situ hybridization. In hypoxic conditions, Fas mes-
senger RNA levels in cardiomyocytes were upregu-
lated by twofold over controls, whereas those of non-
myocytes were downregulated, indicating that cardio-
myocyte death by hypoxia can occur via apoptosis and
that Fas antigen may be associated with the mecha-
nism of this apoptotic process. Zhu et al.(3) reported
that Fas gene expression was detected in the sham-
operated rats and started to over-express at 12 hours
(1.5 - fold in the left ventricle, 2.2-fold in the septum
and 2.4-fold in the right ventricle) aftermyocardial in-
farction compared to sham-operated rats. A significant
overexpression of Fas gene was observed with 1.9-fold
in the left ventricle and 4.7-fold in the septum compared
to sham-operated rats at 72 hours. The results of the
present study show that the upregulation of Fas protein
was observed at 24 hours after myocardial infarction.
The extent of Fas protein expression was coincident
with the number of cardiomyocyte apoptosis, indicating
a role for Fas protein in the regulation of ischemia
induced apoptosis in rats.
Bax is a member of the Bcl-2 family and, when over-
expressed, accelerates cell apoptosis by competing
with Bcl-2 (25, 26). In a recent study in an animal
model of myocardial infarction, Zhu et al. (3) reported
that no Bax gene expression was found in the sham
operated rats and rats 12-hour postmyocardial infarction.
An overexpressedBax genewas detected at 24 hours,
but its level declined at 72 hours after myocardial in-
farction. Gene expression level of Bax was 4.3-fold
(left ventricle), 1.7-fold (septum and right ventricle)
at 24 hours compared to that at 72 hours aftermyocardial
infarction. As mentioned earlier, apoptosis is a highly
regulated process in which several regulatory proteins
play a part, and in which the balance between an array
of regulatory proteins decides the fate of the cell. Recent
studies have documented that themechanismof apop-
tosis regulation of Bcl-2 and Bax not only depends on
themselves’expression levels, but also the ratio of
Bcl-2 to Bax. Apoptosis was inhibited when the ratio
augmented, on the contrary, increased (27).WhileBax-
Bax homodimers act as apoptosis inducers, Bcl-2-Bax
heterodimer formation evokes a survival signal for
the cells. Both Bcl-2 and Bax are transcriptional targets
for the tumor suppressor protein, P53, which induces
cell cycle arrest or apoptosis in response toDNAdamage.
In all, the coordinate performance of thesemolecules
is crucial for controlling life and death of a cell (28, 29).
The current investigation shows that the expression
of Bax protein was significantly increased at 24 hours
after myocardial infarction. Apoptosis was accompanied
by an increase in the expression of Bax, indicating a role
for this protein in the regulation of ischemia induced
apoptosis in rats. Pretreatment with CT-1 for 7 days
is capable of significantly inhibiting Bax expression
as well as reducing cardiomyocyte apoptosis.
Bcl-2 is the most important gene that inhibits apop-
tosis. It can inhibit cardiomyocyte apoptosis caused
by both oxygen free radicals and P53. Recent report
has indicated that ischemic preconditioning resulted
upregulation of Bcl-2 gene. The upregulation of Bcl-2
significantly inhibited the extent of cardiomyocyte
apoptosis induced by both ischemia/reperfusion (30),
suggesting that Bcl-2 can protect cardiomyocytes.
The present study shows that the expression of Bcl-2
protein was increased at 24 hours after myocardial
infarction. Pretreatment withCT-1 for 7 days is capable
of significantly increasing Bcl-2 protein expression as
well as reducing cardiomyocyte apoptosis, suggesting
that Bcl-2 protein has an important role in the regulation
of ischemia induced cardiomyocyte apoptosis. Induction
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of Bcl-2 from cardiomyocytes may become a new
pathway of myocardial preservation.
In conclusion, the present study shows that pretreat-
ment with CT-1 for 7 days is capable of significantly
improving hemodynamicsandcardiac function ; reducing
cardiomyocyte apoptosis ; inhibiting myocardial P53,
Fas andBax expression ; and increasingBcl-2 expression
in the rat model of acute myocardial infarction. CT-1
has a possible cardioprotective effect in this model.
At present, however, the exact mechanism by which
CT-1 causes this cardioprotective effect is still needed
to further determine.
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